Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $3.7 million.

  • Aytu Biopharma's Free Cash Flow rose 2618.14% to $3.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$698000.0, marking a year-over-year decrease of 44554.46%. This contributed to the annual value of -$2.2 million for FY2025, which is 2609.2% down from last year.
  • Aytu Biopharma's Free Cash Flow amounted to $3.7 million in Q4 2025, which was up 2618.14% from -$618000.0 recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Free Cash Flow peaked at $19.7 million during Q1 2021, and registered a low of -$9.1 million during Q3 2022.
  • In the last 5 years, Aytu Biopharma's Free Cash Flow had a median value of -$867500.0 in 2024 and averaged -$416800.0.
  • In the last 5 years, Aytu Biopharma's Free Cash Flow soared by 224740.74% in 2024 and then tumbled by 246850.39% in 2025.
  • Aytu Biopharma's Free Cash Flow (Quarter) stood at -$8.8 million in 2021, then skyrocketed by 72.18% to -$2.5 million in 2022, then surged by 94.49% to -$135000.0 in 2023, then soared by 2247.41% to $2.9 million in 2024, then increased by 26.18% to $3.7 million in 2025.
  • Its Free Cash Flow stands at $3.7 million for Q4 2025, versus -$618000.0 for Q3 2025 and $2.8 million for Q2 2025.